Proteomics: Applications in transfusion medicine

Blood Transfusion

Volumn 6, Issue 2, 2008, Pages 70-85

  Liumbruno, Giancarlo Maria ^a,b  

^a Servizio di Immunoematologia e Medicina Trasfusionale   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTHROMBIN COMPLEX;

BLOOD; BLOOD TRANSFUSION; CD34 SELECTION; ERYTHROCYTE; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; MASS SPECTROMETRY; MEDICAL RESEARCH; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SEPARATION TECHNIQUE; THROMBOCYTE;

BLOOD PROTEINS; BLOOD TRANSFUSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ERYTHROCYTES; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 47749095952     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0038-07     Document Type: Review

References (176)

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Venter JC, Adams MD, Meyers EW, et al. The sequence of human genome. Science 2001; 291: 1304-51.
3. Thadikkaran L, Siegenthaler MA, Crettaz D, et al. Recent advances in blood-related proteomics. Proteomics 2005; 5: 3019-34.
4. Reddy KS, Perrotta PL. Proteomics in transfusion medicine. Transfusion 2004; 44: 601-4.
5. Elek G, Lapis K. A path or a new road in laboratory diagnostics? Biological mass spectrometry: facts and perspectives. Pathol Oncol Res 2006; 12: 179-83.
6. Wilkins MR, Sanchez JC, Gooley AA, et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996; 13: 19-50.
7. Page MJ, Griffiths TAM, Bleackley MR, et al. Proteomics: applications relevant to transfusion medicine. Transfus Med Rev 2006; 20: 63-74.
8. Cristea IM, Gaskell SJ, Whetton AD. Proteomics techniques and their application to hematology. Blood 2004; 103: 3624-34.
9. Marko-Varga G, Fehniger TE. Proteomics and disease: the challenges for technology and discovery. J Proteome Res 2004; 3: 167-78.
10. Salzano AM, Crescenzi M. Mass spectrometry for protein identification and the study of post translational modifications. Ann Ist Super Sanità 2005; 41: 443-50.
11. Elrick MM, Walgren JL, Mitchell MD, et al. Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol 2006; 98: 432-41.
12. Thiele T, Steil L, Völker U, Greinacher A. Proteomics of blood-based therapeutics. BioDrugs 2007; 21: 179-93.
13. Anstee DJ. Whatomics. Vox Sang 2004; 87 (Suppl 1): S13-4.
14. Greinacher A, Warkentin TE. Transfusion medicine in the era of genomics and proteomics. Transfus Med Rev 2005; 19: 288-94.
15. Queloz PA, Thadikkaran L, Crettaz D, et al. Proteomics and transfusion medicine: future perspectives. Proteomics 2006; 6: 5605-14.
16. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250: 4007-21.
17. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002; 2: 3-10.
18. Diezel W, Kopperschläger G, Hofmann E. An improved procedure for protein staining in polyacrylamide gels with a new type of Coomassie brilliant blue. Anal Biochem 1972; 48: 617-20.
19. Berggren KN, Schulenberg B, Lopez MF, et al. An improved formulation of SYPRO Ruby protein gel stain: comparison with the original formulation and with a ruthenium II tris (bathophenanthroline disulfonate) formulation. Proteomics 2002; 2: 486-98.
20. Lopez MF, Berggren K, Chernokalskaya E, et al. A comparison of silver stain and SYPRO Ruby protein gel stain with respect to protein detection in two-dimensional gels and identification by peptide mass profiling. Electrophoresis 2000; 21: 3673-83.
21. Lanne B, Panfilov O. Protein staining influences the quality of mass spectra obtained by peptide mass fingerprint after separation on 2-d gels. A comparison of staining with Coomassie brilliant blue and Sypro ruby. J Proteome Res 2005; 4: 175-9.
22. Benga G, Banner M, Wrigglesworth JM. Quantitation of the water channel protein aquaporin (CHIP8) from red blood cell membranes by densitometry of silver stained polyacrylamide gels. Electrophoresis 1996; 17: 715-9.
23. Dutt MJ, Lee KH. The scaled volume as an image analysis variable for detecting changes in protein expression levels by silver stain. Electrophoresis 2001; 22: 1627-32.
24. Rabilloud T. Mechanisms of protein silver staining in polyacrylamide gels: a 10-year synthesis. Electrophoresis 1990; 11: 785-94.
25. Yan JX, Wait R, Berkelman T, et al. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 2000; 21: 3666-72.
26. Nishihara JC, Champion KM. Quantitative evaluation of proteins in one- and two-dimensional polyacrylamide gels using a fluorescent stain. Electrophoresis 2002; 23: 2203-15.
27. Yan JX, Harry RA, Spibey C, et al. Postelectrophoretic staining of proteins separated by two-dimensional gel electrophoresis using SYPRO dyes. Electrophoresis 2000; 21: 3657-65.
28. Unlü M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-7.
29. Alban A, David SO, Bjorkesten L, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003; 3: 36-44.
30. Shaw J, Rowlinson R, Nickson J, et al. Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. Proteomics 2003; 3: 1181-95.
31. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for functional analysis of the genome. Electrophoresis 1995; 16: 1034-59.
32. Rees-Unwin KS, Morgan GJ, Davies FE. Proteomics and the haematologist. Clin Lab Haem 2004; 26: 77-86.
33. Hoving S, Voshol H, van Oostrum J. Towards high performance two-dimensional gel electrophoresis using ultrazoom gels. Electrophoresis 2000; 21: 2617-21.
34. Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2003; 1: 377-96.
35. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-67.
36. Chromy BA, Gonzales AD, Perkins J, et al. Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J Proteome Res 2004; 3: 1120-7.
37. Ahmed N, Barker G, Oliva K, et al. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 2003; 3: 1980-7.
38. Merrell K, Southwick K, Graves SW, et al. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 2004; 15: 238-48.
39. Zhou M, Lucas DA, Chan KC, et al. An investigation into the human serum "interactome". Electrophoresis 2004; 25: 1289-98.
40. Zhang H, Yi EC, Li XJ, et al. High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol Cell Proteomics 2005; 4: 144-55.
41. Molina H, Bunkerborg J, Reddy GH, et al. A proteomic analysis of human hemodialysis fluid. Mol Cell Proteomics 2005; 4: 637-50.
42. Righetti PG, Castagna A, Antonioli P, et al. Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 2005; 26: 297-319.
43. Björhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005; 5: 307-17.
44. Fountoulakis M, Juranville JF, Jiang L, et al. Depletion of the high-abundance plasma proteins. Amino Acids 2004; 27: 249-59.
45. Baussant T, Bougueleret L, Johnson A, et al. Effective depletion of albumin using a new-peptide-based affinity medium. Proteomics 2005; 5: 973-7.
46. Chen YY, Lin SY, Yeh YY, et al. A modified protein precipitation procedure for efficient removal of albumin from serum. Electrophoresis 2005; 26: 2117-27.
47. Echan LA, Tang HY, Ali-Khan N, et al. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005; 5: 3292-303.
48. Fu Q, Garnham CP, Elliott ST, et al. A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis. Proteomics 2005; 5: 2656-64.
49. Huang HL, Stasyk T, Morandell S, et al. Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. Electrophoresis 2005; 26: 2843-9.
50. Ramström M, Hagman C, Mitchell JK, et al. Depletion of high-abundant proteins in body fluids prior to liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. J Proteome Res 2005; 4: 410-6.
51. Govorukhina NI, Reijmers TH, Nyangoma SO, et al. Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J Chromatogr A 2006; 1120: 142-50.
52. Fu Q, Bovenkamp DE, Van Eyk JE. A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis. Methods Mol Biol 2007; 357: 365-71.
53. Roe MR, Griffin TJ. Gel-free mass spectrometry-based high throughput proteomics. Tools for studying biological response of proteins and proteomes. Proteomics 2006; 6: 4678-87.
54. Stasyk T, Huber LA. Zooming in: fractionation strategies in proteomics. Proteomics 2004; 4: 3704-16.
55. Martosella J, Zolotarjova N, Liu H, et al. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 2005; 4: 1522-37.
56. Link AJ, Eng J, Schieltz DM, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999; 17: 676-82.
57. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 242-7.
58. McCormack AL, Schieltz DM, Goode B, et al. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem 1997; 15: 767-76.
59. Gevaert K, Van Damme J, Goethals M, et al. Chromatographic isolation of methionine-containing peptides for gel-free proteome analysis: identification of more than 800 Escherichia coli proteins. Mol Cell Proteomics 2002; 1: 896-903.
60. Gevaert K, Goethals M, Martens L, et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol 2003; 21: 566-9.
61. Pasini EM, Kirkegaard M, Mortensen P, et al. In-depth analysis of the membrane and cytosolic proteome of red blood cells. Blood 2006; 108: 791-801.
62. Fenn JB, Mann M, Meng CK, et al. Electrospray ionization for the mass spectrometry of large biomolecules. Science 1989; 246: 64-71.
63. Karas M, Hillenkamp F. Laser desorption ionizations of proteins with molecular mass exceeding 10,000 daltons. Anal Chem 1989; 60: 2299-301.
64. Baharvand H, Fathi A, van Hoof D, et al. Concise review: trends in stem cell proteomics. Stem Cells 2007; 25: 1888-903.
65. Hu Q, Noll RJ, Li H, et al. The Orbitrap: a new mass spectrometer. J Mass Spectrom 2005; 40: 430-43.
66. May D, Fitzgibbon M, Liu Y, et al. A platform for accurate mass and time analyses of mass spectrometry data. J Proteome Res 2007; 6: 2685-94.
67. Perrotta PL, Bahou WF. Proteomics in platelet science. Curr Hematol Rep 2004; 3: 462-9.
68. Petrik J. Diagnostic applications of microarrays. Transfus Med 2006; 16: 233-47.
69. Petrik J. Microarray technology: the future of blood testing? Vox Sang 2001; 80: 1-11.
70. LaBaer J, Ramachandran N. Protein microarrays as a tool for functional proteomics. Curr Opin Chem Biol 2005; 9: 14-9.
71. Binz HK, Stumpp MT, Forrer P, et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003; 332: 489-503.
72. Mayer G, Jenne A. Aptamers in research and drug development. BioDrugs 2004; 18: 351-9.
73. Bock C, Coleman M, Collins B, et al. Photoaptamers arrays applied to multiplexed proteomic analysis. Proteomics 2004; 4: 609-18.
74. Jin M, Cataland S, Bissell M, et al. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost 2006; 4: 333-8.
75. Adam GC, Sorensen EJ, Cravatt BF. Chemical strategies for functional proteomics. Mol Cell Proteomics 2002; 1: 781-90.
76. Adam GC, Sorensen EJ, Cravatt BF. Trifunctional chemical probes for the consolidated detection and identification of enzyme activities from complex proteomes. Mol Cell Proteomics 2002; 1: 828-35.
77. Rosenblum BB. Two-dimensional gel electrophoresis of erythrocyte membrane proteins. Prog Clin Biol Res 1981; 56: 251-68.
78. Low TY, Seow TK, Chung MC. Separation of human erythrocyte membrane associated proteins with one-dimensional and two-dimensional gel electrophoresis followed by identification with matrix-assisted laser desorption/ionization- time of flight mass spectrometry. Proteomics 2002; 2: 1229-39.
79. Kakhniashvili DG, Bulla LA Jr, Goodman SR. The human erythrocyte proteome: analysis by ion trap mass spectrometry. Mol Cell Proteomics 2004; 3: 501-9.
80. Tyan JH, Jong SB, Liao PC, et al. Proteomic profiling of erythrocyte proteins by proteolytic digestion chip and identification using two-dimensional electrospray ionization tandem mass spectrometry. J Proteome Res 2005; 4: 748-57.
81. Kakhniashvili DG, Griko NB, Bulla LA Jr, et al. The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp Biol Med 2005; 230: 787-92.
82. Körbel S, Büchse T, Prietzsch H, et al. Phosphoprotein profiling of erythropoietin receptor-dependent pathways using different proteomic strategies. Proteomics 2005; 5: 91-100.
83. Florens L, Liu X, Wang Y, et al. Proteomics approach reveals novel proteins on the surface of malaria-infected erythrocytes. Mol Biochem Parasitol 2004; 135: 1-11.
84. Florens L, Washburn MP, Raine JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002; 419: 520-6.
85. Jiang M, Jia L, Jiang W, et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun 2003; 309: 196-200.
86. Brand M, Ranish JA, Kummer NT, et al. Dynamic changes in transcription factor complexes during erythroid differentiation revealed by quantitative proteomics. Nat Struct Mol Biol 2004; 11: 73-80.
87. Annis AM, Glenister KM, Killian JJ, et al. Proteomic analysis of supernatants of stored red blood cell products. Transfusion 2005; 45: 1426-33.
88. D'Amici GM, Rinalducci S, Zolla L. Proteomic analysis of RBC membrane protein degradation during blood storage. J Proteome Res 2007; 6:3242-55..
89. Schenk BI, Petersen F, Flad HD, et al. Platelet-derived chemokines CXC chemokine ligand (CXC)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol 2002; 169: 2602-10.
90. Sparrow RL, Patton KA. Supernatant from stored red blood cell primes inflammatory cells: influence of prestorage white cell reduction. Transfusion 2004; 44: 722-30.
91. Annis AM, Sparrow RL. Storage duration and white blood cell content of red blood cell (RBC) products increases adhesion of stored RBCs to endothelium under flow conditions. Transfusion 2006; 46: 1561-7.
92. Yoshida T, AuBuchon JP, Tryzelaar L, et al. Extended storage of red blood cells under anaerobic conditions. Vox Sang 2007; 92: 22-31.
93. Clemetson KJ, Capitanio A, Lüscher EF. High resolution two-dimensional gel electrophoresis of the proteins and glycoproteins of human blood platelets and platelet membranes. Biochim Biophys Acta 1979; 553: 11-24.
94. Watson SP, Bahou WF, Fitzgerald D, et al. Mapping the platelet proteome: a report of the ISTH platelet physiology subcommittee. J Thromb Haemost 2005; 3: 2098-101.
95. Gnatenko DV, Perrotta PL, Bahou WF. Proteomic approaches to dissect platelet function: half the story. Blood 2006; 108: 3983-91.
96. Gravel P, Sanchez JC, Walzer C, et al. Human blood platelet protein map established by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1995; 16: 1152-9.
97. Immler D, Gremm D, Kirsch D, et al. Identification of phosphorylated proteins from thrombin-activated human platelets isolated by two-dimensional gel electrophoresis by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) and liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). Electrophoresis 1998; 19: 1015-23.
98. Marcus K, Immler D, Sternberger J, et al. Identification of platelet proteins separated by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis 2000; 21: 2622-36.
99. O'Neill EE, Brock CJ, von Kriegsheim AF, et al. Towards complete analysis of the platelet proteome. Proteomics 2002; 2: 288-305.
100. García A, Prabhakar S, Brock CJ, et al. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004; 4: 656-68.
101. Maguire PB, Wynne KJ, Harney DF, et al. Identification of the phosphotyrosine proteome for thrombin activated platelets. Proteomics 2002; 2: 642-8.
102. Marcus K, Moebius J, Meyer HE. Differential analysis of phosphorylated proteins in resting and thrombin-stimulated human platelets. Anal Bioanal Chem 2003; 376: 973-93.
103. García A, Prabhakar S, Hughan S, et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood 2004; 103: 2088-95.
104. García A, Senis YA, Antrobus R, et al. A global proteomics approach identifies novel phosphorylated signalling proteins in GPVI-activated platelets: involvement of G6f, a novel platelet Grb2-binding membrane adapter. Proteomics 2006; 6: 5332-43.
105. García A. Proteome analysis of signalling cascades in human platelets. Blood Cells Mol Dis 2006; 36: 152-6.
106. Lewandrowski U, Moebius J, Walter U, et al. Elucidation of N-glycosylation sites on human platelet proteins. Mol Cell Proteomics 2006; 5: 226-33.
107. Moebius J, Zahedi RP, Lewandrowski U, et al. The human platelet membrane proteome reveals several new potential membrane proteins. Mol Cell Proteomics 2005; 4: 1754-61.
108. García A, Zitzmann N, Watson SP. Analyzing the platelet proteome. Semin Thromb Haemost 2004; 30: 485-9.
109. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
110. Garcia BA, Smalley DM, Cho H, et al. The platelet microparticle proteome. J Proteome Res 2005; 4: 1516-21.
111. García A, Watson SP, Dwek RA, et al. Applying proteomics technology to platelet research. Mass Spectrom Rev 2005; 24: 918-30.
112. Macaulay IC, Carr P, Gusnanto A, et al. Platelet genomics and proteomics in human health and disease. J Clin Invest 2005; 115: 3370-7.
113. Macaulay IC, Carr P, Farrugia R, et al. Analysing the platelet transcriptome. Vox Sang 2004; 87 (Suppl 2): S42-6.
114. Lindemann S, Gawaz M. The active platelet: translation and protein synthesis in an anucleate cell. Semin Thromb Haemost 2007; 33: 144-50.
115. Thiele T, Steil L, Gebhard S, et al. Profiling of alteration in platelet proteins during storage of platelet concentrates. Transfusion 2007; 47: 1221-33.
116. Holme S, Vaidja K, Murphy S. Platelet storage at 22°C: effect of type of agitation on morphology, viability, and function in vitro. Blood 1978; 52: 425-35.
117. Klinger MH. The storage lesions of platelets: ultrastructural and functional aspects. Ann Hematol 1996; 73: 103-12.
118. Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev 1997; 11: 130-44.
119. Cardigan R, Turner C, Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005; 88: 153-63.
120. Snyder EL, Dunn BE, Giometti CS, et al. Protein changes occurring during storage of platelet concentrates. A two-dimensional gel electrophoresis analysis. Transfusion 1987; 27: 335-41.
121. Wurtz V, Hechler B, Ohlmann P, et al. Identification of platelet factor 4 and â-thromboglobulin by profiling and liquid chromatography tandem mass spectrometry of supernatant peptides in stored apheresis and buffy-coat platelet concentrates [letter]. Transfusion 2007; 47: 1099-100.
122. Farrugia A. Plasma for fractionation: safety and quality issues. Haemophilia 2004; 10: 334-40.
123. Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci USA 1977; 74: 5421-5.
124. Qian WJ, Jacobs JM, Liu T, et al. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006; 5: 1727-44.
125. Li X, Gong Y, Wang Y, et al. Comparison of alternative analytical techniques or the characterization of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 2005; 5: 3423-41.
126. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006; 52: 1223-37.
127. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 947-55.
128. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005; 5: 3226-45.
129. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006; 35: 83-90.
130. Tissot JD, Hochstrasser DF, Schneider B, et al. No evidence for protein modifications in fresh frozen plasma after photochemical treatment: an analysis by high-resolution two-dimensional electrophoresis. Br J Haematol 1994; 86: 143-6.
131. Wagner SJ, Cifone MA, Murli H, et al. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion 1995; 35: 407-13.
132. AuBuchon JP, Pickard C, Herschel L, et al. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang 1998; 74: 1-6.
133. Riggert J, Humpe A, Legler TJ, et al. Filtration of methylene blue-photo oxidized plasma: influence on coagulation and cellular contamination. Transfusion 2001; 41: 82-6.
134. Crettaz D, Sensebe L, Vu DH, et al. Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics 2004; 4: 881-91.
135. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21: 101-17.
136. Brigulla M, Thiele T, Scharf C, et al. Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion 2006; 46: 377-85.
137. United Kingdom Haemophilia Centre Doctors' Organization (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
138. Baglin T, Keeling DM, Watson HG; British Committee for Standards in Haematology. Guideline on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006; 132: 277-85.
139. 139) Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-70.
140. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48.
141. Viguè B, Ract C, Tremey B, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33: 721-5.
142. Köhler M, Hellstern P, Lechler E, et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998; 80: 399-402.
143. 1-proteinase inhibitor products used for replacement therapy. Transfusion 2006; 46: 1959-77.
144. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006; 46: 741-53.
145. Gürcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007; 41: 812-23.
146. Hume HA, Anderson DR. Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 2007; 21 (Suppl 1): S1-2.
147. Robinson P, Anderson D, Brouwers M, et al; IVIG Hematology and Neurology Expert Panels. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 2007; 21 (Suppl 1): S3-8.
148. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007; 21 (Suppl 1): S9-56.
149. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007; 21 (Suppl 1): S57-107.
150. Sapan CV, Reisner HM, Lundblad RL. Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics. Vox Sang 2007; 92: 197-205.
151. Hübel K, Dale DC, Liles WC. Granulocyte transfusion therapy: update on potential clinical applications. Curr Opin Hematol 2001; 8: 161-4.
152. Price TH. Granulocyte transfusion: current status. Semin Hematol 2007; 44: 15-23.
153. Hübel K, Rodger E, Gaviria JM, et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion 2005; 45: 1876-89.
154. th, 2005.
155. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000; 21: 665-72.
156. Singh S, Powell DW, Rane MJ, et al. Identification of the p16-Arc subunit of the Arp 2/3 complex as a substrate of MAPK-activated protein kinase 2 by proteomic analysis. J Biol Chem 2003; 278: 36410-7.
157. Avram D, Romijn EP, Pap EH, et al. Identification of proteins in activated human neutrophils susceptible to tyrosyl radical attack. A proteomic study using a tyrosylating fluorophore. Proteomics 2004; 4: 2397-407.
158. Lominadze G, Powell DW, Luerman GC, et al. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics 2005; 4: 1503-21.
159. Lominadze G, Ward RA, Klein JB, et al. Proteomic analysis of human neutrophils. Methods Mol Biol 2006; 332: 343-56.
160. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-75.
161. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813-20.
162. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106.
163. Lian Z, Wang L, Yamaga S, et al. Genomic and proteomic analysis of the myeloid differentiation program. Blood 2001; 98: 513-24.
164. Lian Z, Kluger Y, Greenbaum DS, et al. Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. Blood 2002; 100: 3209-20.
165. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004; 3: 960-9.
166. Unwin RD, Smith DL, Blinco D, et al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood 2006; 107: 4687-94.
167. Unwin RD, Whetton AD. Systematic proteome and transcriptome analysis of stem cell populations. Cell Cycle 2006; 5: 1587-91.
168. Zenzmaier C, Kollroser M, Gesslbauer B, et al. Preliminary 2-D chromatographic investigation of the human stem cell proteome. Biochem Biophys Res Commun 2003; 310: 483-90.
169. Zenzmaier C, Gesslbauer B, Grobushek N, et al. Proteomic profiling of human stem cells derived from umbilical cord blood. Biochem Biophys Res Commun 2005; 328: 968-72.
170. + myeloid cells. Stem Cells 2004; 22: 1003-14.
171. + hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome. Proteomics 2006; 6: 2673-92.
172. Rollini P, Kaiser S, Faes-van't Hull E, et al. Long-term expansion of transplantable human fetal liver hematopoietic stem cells. Blood 2004; 103: 1166-70.
173. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20: 1-26.
174. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion 2006; 46: 143-52.
175. Jin M, Drwal G, Bourgeois T, et al. Distinct proteome features of plasma microparticles. Proteomics 2005; 5: 1940-52.
176. Banfi C, Brioschi M, Wait R, et al. Proteome of endothelial cell-derived procoagulant microparticles. Proteomics 2005; 5: 4443-55.